Form 4: Kura Oncology Chief Medical Officer Sells Shares to Cover Taxes

Mollie Leoni, Chief Medical Officer of Kura Oncology, sold a total of 4,963 shares of common stock on January 28, 2025, to cover taxes associated with the vesting of restricted stock units.

Summary

• Mollie Leoni, the Chief Medical Officer of Kura Oncology, sold 4,963 shares of common stock on January 28, 2025.
• The sales were executed at a price of $7.8719 per share.
• These transactions were made to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
• The sales were related to RSUs granted on January 2, 2024, January 26, 2022, February 16, 2023, and January 26, 2021.
• Following these transactions, Ms. Leoni directly owns 88,253 shares of Kura Oncology common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for an executive to cover tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for company executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when RSUs vest.

Comparison to Industry Standards

• Similar transactions are common across the biotechnology and pharmaceutical industries where stock-based compensation is a significant part of executive pay.
• Many executives at comparable companies such as Mirati Therapeutics, Deciphera Pharmaceuticals, and Blueprint Medicines also regularly sell shares to cover taxes related to vesting RSUs.
• These transactions are typically disclosed via SEC Form 4 filings.

Stakeholder Impact

• The stock sale by the Chief Medical Officer is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Kura Oncology, Mollie Leoni, Chief Medical Officer, stock sale, Form 4, insider trading, restricted stock units, RSU, tax obligations